磷霉素与碳青霉烯类联合用药对碳青霉烯类不敏感大肠埃希菌和肺炎克雷伯菌的体外活性 - Suppr | 超能文献

In vitro activities of fosfomycin and carbapenem combinations against carbapenem non-susceptible Escherichia coli and Klebsiella pneumoniae.

作者信息

Netikul Thidarat, Leelaporn Amornrut, Leelarasmee Amorn, Kiratisin Pattarachai

出版信息

Int J Antimicrob Agents. 2010 Jun;35(6):609-10. doi: 10.1016/j.ijantimicag.2010.01.021. Epub 2010 Mar 1.

DOI:10.1016/j.ijantimicag.2010.01.021

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

In vitro activities of fosfomycin and carbapenem combinations against carbapenem non-susceptible Escherichia coli and Klebsiella pneumoniae.

Int J Antimicrob Agents. 2010 Jun;35(6):609-10. doi: 10.1016/j.ijantimicag.2010.01.021. Epub 2010 Mar 1.

2

In vitro activity of fosfomycin against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures.

Antimicrob Agents Chemother. 2006 Jan;50(1):368-70. doi: 10.1128/AAC.50.1.368-370.2006.

3

Carbapenem resistance among Escherichia coli and Klebsiella pneumoniae in a tertiary care hospital in south India.

Indian J Med Microbiol. 2012 Jan-Mar;30(1):93-5. doi: 10.4103/0255-0857.93054.

4

In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan.

J Microbiol Immunol Infect. 2006 Feb;39(1):59-66.

5

Carbapenem-resistant Escherichia coli and Klebsiella pneumoniae isolates from Turkey with OXA-48-like carbapenemases and outer membrane protein loss.

Int J Antimicrob Agents. 2008 Jun;31(6):523-6. doi: 10.1016/j.ijantimicag.2008.01.017. Epub 2008 Mar 12.

6

Sequence type 101 (ST101) as the predominant carbapenem-non-susceptible Klebsiella pneumoniae clone in an acute general hospital in Italy.

Int J Antimicrob Agents. 2012 Jun;39(6):543-5. doi: 10.1016/j.ijantimicag.2012.02.012. Epub 2012 Apr 23.

7

Prevalent phenotypes and antibiotic resistance in Escherichia coli and Klebsiella pneumoniae at an Indian tertiary care hospital: plasmid-mediated cefoxitin resistance.

Int J Infect Dis. 2008 May;12(3):256-64. doi: 10.1016/j.ijid.2007.08.008. Epub 2007 Nov 5.

8

Comparative in vitro killing of carbapenems and aztreonam against Klebsiella pneumoniae producing VIM-1 metallo-beta-lactamase.

Int J Antimicrob Agents. 2007 Mar;29(3):360-2. doi: 10.1016/j.ijantimicag.2006.11.004. Epub 2007 Jan 12.

9

Comparison of CLSI 2009, CLSI 2010 and EUCAST cephalosporin clinical breakpoints in recent clinical isolates of Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca from the SMART Global Surveillance Study.

Int J Antimicrob Agents. 2010 Sep;36(3):293-4. doi: 10.1016/j.ijantimicag.2010.05.012. Epub 2010 Jul 3.

10

Activity of a novel aminoglycoside, ACHN-490, against clinical isolates of Escherichia coli and Klebsiella pneumoniae from New York City.

J Antimicrob Chemother. 2010 Oct;65(10):2123-7. doi: 10.1093/jac/dkq278. Epub 2010 Jul 28.

引用本文的文献

1

Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies.

Antibiotics (Basel). 2020 Aug 10;9(8):500. doi: 10.3390/antibiotics9080500.

2

In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development.

Antimicrob Agents Chemother. 2011 May;55(5):2395-7. doi: 10.1128/AAC.01086-10. Epub 2011 Feb 14.